FDA Approved: ONDANSETRON — Supplemental Application (AvKARE)

View source ↗

Summary

FDA approved a supplemental application for Ondansetron from AvKARE under ANDA078152, authorizing the generic product's marketing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting
• Postoperative Nausea and Vomiting
• Radiation-induced Nausea and Vomiting

Drugs mentioned

• Ondansetron (ondansetron)

Snippet

SUPPL AP for ONDANSETRON (ONDANSETRON)